Mwalimu-G
Elder Lister
https://x.com/Arap_Nyasikera/status/1749895098999926792?s=20
In November, 2023, I managed to buy 3 Ventolin inhalers from Aga Khan, the very last pieces at the time. That pharmtech explained the shortage attributed to GSK's exit. They moved their production to Egypt and downgraded Kenya to mere warehousing location. We are f'kd up
Ventolin, a life-saving asthma drug produced by GlaxoSmithKline (GSK), is currently out of stock in major healthcare outlets in Kenya. This shortage can in part be attributed to GSK's exit from the country late last year, after which the company will rely on third-party distributors to supply its products in the Kenyan market.
GSK's decision to leave was driven by stiff competition from cheap generic alternatives from India, which asthma patients find less effective and tolerable. The absence of Ventolin is concerning for asthma patients, as the medication is essential for managing acute attacks.
The shortages are expected to result in asthma exacerbations, increased hospitalizations, and poor asthma control among affected individuals. The ramifications of GSK's departure from Kenya are extensive and impact the availability of critical medications for the country's healthcare system. It’s sad that the government did nothing to cushion their exit.
In November, 2023, I managed to buy 3 Ventolin inhalers from Aga Khan, the very last pieces at the time. That pharmtech explained the shortage attributed to GSK's exit. They moved their production to Egypt and downgraded Kenya to mere warehousing location. We are f'kd up
Ventolin, a life-saving asthma drug produced by GlaxoSmithKline (GSK), is currently out of stock in major healthcare outlets in Kenya. This shortage can in part be attributed to GSK's exit from the country late last year, after which the company will rely on third-party distributors to supply its products in the Kenyan market.
GSK's decision to leave was driven by stiff competition from cheap generic alternatives from India, which asthma patients find less effective and tolerable. The absence of Ventolin is concerning for asthma patients, as the medication is essential for managing acute attacks.
The shortages are expected to result in asthma exacerbations, increased hospitalizations, and poor asthma control among affected individuals. The ramifications of GSK's departure from Kenya are extensive and impact the availability of critical medications for the country's healthcare system. It’s sad that the government did nothing to cushion their exit.
